Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 9, Issue 2, 1996, Pages 74-80

  Best, J D ^a   Nicholson, G C ^b   O'Neal, D N ^a   Kotowicz, M A ^b   Tebbutt, N C ^a   Chan, K W ^a   Sanders, K M ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b GEELONG HOSPITAL   (Australia)

Author keywords

HMG CoA reductase inhibitors; Hypercholesterolaemia; Non insulin dependent diabetes

Indexed keywords

ATORVASTATIN; CHOLESTEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; MALE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029891503     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Stamler J., Vaccaro O., Neaton J.D., Wentworth D.: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16: 434-444, 1993.
2. Kannel W.B., McGee D.L.: Diabetes and cardiovascular risk factors in the Framingham Study. Circulation 59: 8-13, 1993.
3. West K.M., Ahuja M.M.S., Bennett P.H., Czyzyk A., De Acosta O.M., Fuller J.H., Grab B., Grabauskas V., Jarrett R.J., Kosaka K., Keen H., Krowlewski A.S., Miki E., Schliack V., Teuscher A., Watkins, P.J., Stober, J.A.: The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO Multinational Study. Diabetes Care 6: 361-369, 1983.
4. Jarrett R.J., Shipley M.J.: The Whitehall Study: comparative mortality rates and indices of risk in diabetics. Acta Endocrinol. 110 (Suppl. 272). 21-26, 1985.
5. Rosengren A., Welin L., Tsipogiani A., Wilhelmsen L.: Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: A general population study. Br. Med. J. 299: 1127-1131. 1989.
6. Santon R.J., Willis P.W., Fajans S.S.: Atheroscleiosis in diabetes melhtus. Correlations with serum lipid levels, adiposity and serum insulin level. Arch. Intern. Med. 130: 833-843, 1972.
7. Fontbonne A., Eschwege E., Cambien F., Richard J-L., Ducimetiere P., Thibult N., Warnet J-M., Claude J-R., Rosselin G-E., Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32: 300-304, 1989.
8. Reckless J.P.D., Betteridge D.J., Wu P., Payne B., Galton DJ.: High density and low density lipoproteins, and prevalence of vascular disease in diabetes mellitus. Br. Med. J. 1:883-886, 1978.
9. 2 cholesterol with coronary heart disease in non-insulin-dependent diabetes. Diabetes 28: 836-840, 1979.
10. Welborn T.A., Knuiman M., McCann V., Stanton K., Constable IJ.: Clinical macro vascular disease in Caucasoid diabetic subjects: logistic regression analysis of risk variables. Diabetologia 27: 568-537, 1984.
11. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R.: Diabetes, blood lipids and the role of obesity in coronary heart disease risk for women. The Framingham study. Ann. Intern. Med. 87: 393-397, 1977.
12. Biesbroeck R.C., Albers J.J., Wahl P.W., Weinberg C.R., Bassett M.L., Bierman E.L.: Abnormal concentration of high density lipoproteins in non-insulin-dependent diabetics. Diabetes 31: 126-131, 1982.
13. Barrett-Connor E., Grundy S.M., Holbrook M.J.: Plasma lipids and diabetes mellitus in an adult community. Am. J. Epidemiol. 115: 657-663, 1982.
14. Uusitupa M., Siitonen O., Voutilainen E., Aro A., Hersio K., Pyörälä K., Pentilla I., Ehnholm C.: Serum lipids and lipoproteins in newly diagnosed non-insulin-dependent (type II) diabetic patients, with special reference to factors influencing HDL-Cholesterol and triglyceride levels. Diabetes Care 9: 17-22, 1986.
15. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Manttari M., Heinonen O.P., Frick M.H.: Joint effects of serum triglyceride and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85: 37-45, 1992.
16. Assmann G., Schulte H.: Results and conclusions of the Prospective Cardiovascular Münster (PROCAM) Study. In: Assmann G. (Ed), Lipid metabolism disorders and coronary heart disease, 2nd ed. MMV Medizin Verlag. München, Germany. 1993. pp. 19-67.
17. American Diabetes Association: Clinical practice recommendations. Detection and management of lipid disorders in diabetes (consensus statement). Diabetes Care 16 (Suppl. 2): 106-112, 1993.
18. Yoshino G., Kazumi T., Iwatani I., Iwai M., Inui A., Otsuki M., Baba S.: Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics. Diabetes Res. Clin. Pract. 2: 179-181, 1986.
19. Garg A., Grundy S.M.: Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl. J. Med. 318:81-86, 1988.
20. Yoshino G., Kazumi J., Iwai M., Matsushita M., Matsuba K., Uenoyama R., Iwatani I., Baba S.: Long-term treatment of hypercholesterolemic non-insulin-dependent diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis 75: 67-72, 1989.
21. Goldberg R., La Belle P., Zupkis R., Ronca, P.: Comparison of the effects of lovastatm and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. Am. J. Cardiol. 66 (Suppl. B): 16 B-21B, 1990.
22. Bach L.A., Wirth A., O'Brien R.C., Cooper M.E., Jerums G.: Cholesterol-lowering effects of simvastatin in patients with NIDDM. Diab. Nutr. Metab. 4: 123-128, 1991.
23. Owens D., Stinson J., Collins P., Johnson A., Tomkin G.H.: Improvement in the regulation of cellular cholesterologenesis in diabetes: The effect of reduction in serum cholesterol by simvastatin. Diabetic Med. 8: 151-156, 1991.
24. Paolisso G., Sgambato S., De Rui S., Gambardella A., Verza M., Varricchio M., D'Onofrio F.: Simvastatin reduces plasma lipid levels and improves insulin action in elderly non-insulin-dependent diabetics. Eur. J. Clin. Pharmacol. 40: 27-31, 1991.
25. Steyn K., Weich H.F.H., Bonnici F., Kotze T.J., Stander L. Vermaark W.J., Lourens W., van Lathem J., Omar M.A., Fourie J.: Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia. S. Afr. Med. J. 82: 402-406, 1992.
26. Torri A., Sommariva D., Maraffi F., Montalto C., Acquati C., Prandi W., Gandini R.: Long-term effects of low-dose simvastatin in hypercholesterolemic type-2 diabetic patients. Curr. Ther. Res. 51: 28-36, 1992.
27. Miccoli R., Bertolotto A., Giovannitti M.G., Tedesco L, Manfredi S., Galantini G., Navalesi R.: Simvastatin for lowering cholesterol levels in non-insulin-dependent diabetes meltitus and in primary hypercholesterolemia. Curr. Ther. Res. 51:66-74, 1992.
28. Ikeda T., Ochi H., Ohtani I., Fujiyama K., Hoshino T., Tanaka Y., Takeuchi T., Mashiba H.: Comparison of the effects of small doses of probucol and pravastatin on serum lipids and apolipoproteins in non-obese, non-insulin-dependent diabetes mellitus patients with hypercholesterolemia. Curr. Ther. Res. 51: 593-599, 1992.
29. Zambon S., Lapolla A., Sartore G., Gherardingher C., Cortella A., Mangato E., Crepaldi G., Fedele D.: Long-term treatment with simvastatin in hypercholesterolemic non-insulin-dependent diabetic patients. Curr. Ther. Res. 52: 221-229, 1992.
30. Martini S., Gabelli C., Pagano G.F., Falluca A., Muntoni S., Sarbene E., Briani G., Gattin L., Da Col P., Crepaldi G.: Efficacy and safety of simvastatin for the treatment of hypercholesterolemia in patients with and without type II diabetes. Curr. Ther. Res. 52: 281-290, 1992.
31. Umeda F., Watanabe J., Inoue K., Hisatomi A., Mimura K., Yamauchi T., Sako Y., Kunisaki M., Tajiri Y., Nawata H.: Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes. Endocrinol. Jap. 39: 45-50, 1992.
32. Cassader M., Ruiu R., Gambino R., Alemanno N., Veglia F., Pagano G.: Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels. Atherosclerosis 99: 27-53, 1993.
33. Nielsen S., Schmitz O., Møller N., Porksen N., Klausen I.C., Alberti K.G.M.M., Mogensen C.E.: Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria Diabetologia 36: 1079-1086, 1993.
34. Knopp R.H., Frohlich J., Jokubaitis L.A., Dawson K., Broyles F.E., Gomez-Coronado D.: Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am. J. Med. 96 (Suppl. 6A): 69S-78S, 1994.
35. Daubresse J.C , Machowski R., Pulinx E.: Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hyperchoiesterolemia. Acta Clin. Belg. 49: 68-75, 1994.
36. Bhatnagar D., Durrington P.N., Kumar S., Mackness M.I., Dean J., Boulton A.J.M.: Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 44: 460-465, 1995.
37. Garg A , Grundy S.M.: Management of dyslipidemia in NIDDM. Diabetes Care 13: 153-169, 1990.
38. Bocan T.M.A., Mazur M.J., Mueller S.B., Brown E.Q., Sliskovic D.R., O'Brien P.M., Creswell M.W., Lee H., Uhlendorf P.D., Roth B.D., Newton R.S.: Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylgluaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis 111: 127-142, 1994.
39. Grouse J.R.: Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am. J. Med. 83: 243-248, 1987.
40. Kahn S.E., Beard J.C., Schwartz M.W., Ward W.K., Ding H.L., Bergman R.N., Taborsky Jr. G.J., Porte Jr. D.: Increased B-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 38: 562-568, 1989.
41. Garg A., Grundy S.M.: Nicotinic acid as therapy for dyslipidemia in NIDDM. JAMA 264: 723-726, 1990.
42. Garg A., Grundy S.M.: Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Diabetes 38: 364-372, 1989.
43. Grundy S.M.: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 319: 24-32, 1988.
44. The Pravastatin Multinational Study Group for Cardiac Risk Patients: Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am. J. Cardiol. 72: 1031-1037, 1993.
45. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994.
46. Bocan T.M., Ferguson E., McNally W., Uhlendorf P.D., Bak-Mueller S., Dehart P., Sliskovic D.R., Roth B.D., Krause B.R., Newton R S.: Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim. Biophys. Acta 1123: 133-144, 1992.
47. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz D.L., Lupien P-J. Jones P.H., Haber H.E., Black D.M.: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15: 678-682, 1995.